Navigation Links
Inventor of Newly Available Vimpat(R) (lacosamide) C-V Meets a Woman Who Experienced Greater Seizure Control With Use of This New Antiepileptic Drug
Date:5/26/2009

ATLANTA, May 26 /PRNewswire/ --

About Dr. Harold Kohn & Vimpat

Almost twenty years after discovering a new chemical compound that affects neurological systems, Harold Kohn, Ph.D., University of North Carolina at Chapel Hill, inventor of the recently FDA-approved Vimpat(R) (lacosamide)C-V, meets Veronica Crowe, whose life has changed significantly with the use of the drug. Dr. Kohn was moved to hear her story of perseverance, and Veronica was thrilled to thank the man whose discovery helped her achieve greater seizure control. Vimpat is now available as an add-on therapy for the treatment of partial-onset seizures in adults 17 years and older with epilepsy.

(Photo: http://www.newscom.com/cgi-bin/prnh/20090526/NY22568 )

The approval of Vimpat was based on safety and efficacy data from three pivotal trials with approximately 1,300 patients. In the studies, seizures were reduced by half or more for many patients taking Vimpat, and they experienced reductions in median seizure frequency at rates significantly greater than those in the placebo groups. Across these trials, some patients taking Vimpat at 200mg/day and 400mg/day were seizure free throughout the 12-week maintenance phase.

Vimpat demonstrated efficacy and tolerability when combined with a broad range of existing antiepileptic drugs (AEDs).

The most common adverse reactions occurring in greater than or equal to 10 percent of Vimpat-treated patients, and greater than placebo, were dizziness, headache, nausea, and diplopia.

About Epilepsy

Epilepsy is a chronic neurological disorder affecting approximately three million people in the U.S.

  • Epilepsy can affect anyone at any time; it is a common neurological condition that can last a patient's entire life
  • Less than half (47%) of patients with epilepsy will attain seizure control with their first AED
  • More than 30% of patients will continue to experience seizures despite trying two or more AEDs
  • Each year, epilepsy is diagnosed in 200,000 new patients, a number that is expected to rise as the population ages

Important Safety Information About Vimpat in the U.S.

Vimpat tablets are indicated as adjunctive therapy in the treatment of partial-onset seizures in patients with epilepsy who are 17 years and older. Vimpat injection is indicated as short-term replacement when oral administration is not feasible in these patients. Patients should be advised that Vimpat may cause dizziness, ataxia, and syncope. Caution is advised for patients with known cardiac conduction problems, who are taking drugs known to induce PR interval prolongation, or with severe cardiac disease. In patients with seizure disorders, Vimpat should be gradually withdrawn to minimize the potential of increased seizure frequency. Multiorgan hypersensitivity reactions have been reported with antiepileptic drugs. If this reaction is suspected, treatment with Vimpat should be discontinued.

AEDs increase the risk of suicidal behavior and ideation. Patients taking Vimpat should be monitored for the emergence or worsening of depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior.

The most common adverse reactions occurring in greater than or equal to 10 percent of Vimpat-treated patients, and greater than placebo, were dizziness, headache, nausea, and diplopia.

For more information, and prescribing information visit www.Vimpat.com or contact UCB at (800) 477-7877.

Vimpat(R) is a registered trademark under license from Harris FRC Corporation.

Further Information

    Andrea Levin, Public Relations Manager, CNS, UCB
    Phone: 770-970-8352
    Email: andrea.levin@ucb.com

    Sarah Handza, Cooney Waters Group
    Phone: 212-886-2206
    Email: shandza@cooneywaters.com

About UCB

UCB, Brussels, Belgium (www.ucb.com) is a biopharmaceutical company dedicated to the research, development and commercialization of innovative medicines with a focus on the fields of central nervous system and immunology disorders. Employing more than 10,000 people in over 40 countries, UCB achieved revenue of 3.6 billion Euro in 2008. UCB is listed on Euronext Brussels (symbol: UCB).

Forward Looking Statement

This press release contains forward-looking statements based on current plans, estimates and beliefs of management. Such statements are subject to risks and uncertainties that may cause actual results to be materially different from those that may be implied by such forward-looking statements contained in this press release. Important factors that could result in such differences include: changes in general economic, business and competitive conditions, effects of future judicial decisions, changes in regulation, exchange rate fluctuations and hiring and retention of its employees.


'/>"/>
SOURCE UCB
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Management Health Solutions, Inc. Announces Release v1.0 to Clinical Inventory Valuation Solution
2. LANAP Inventors Call ADAs Laser Position Statement Flawed
3. Inventor Sues Therative, Inc. Over Inventorship of Patent on ThermaClear Device; Separate Invention Theft Case Continues
4. ASAP Systems now Offers Flexible Payment Options for its Barcode Inventory, Asset and Evidence Tracking Solutions Through a Strategic Microsoft Financing™ Partnership
5. IntegriChain Announces Measurement of Retail Inventory(TM) (MRI) Analytic
6. Mercy Regional Medical Center Selects Management Health Solutions, Inc. for Inventory Services
7. ACell, Inc. Founder Mentioned on the Oprah Winfrey Show as Inventor of Powder for Healing Severed Fingers
8. Inventor of G-Suit Dies
9. ASAP Systems Passport Gets Cutting-Edge Mobile Inventory, Asset and Property Tracking Software
10. SmartOps Enterprise Inventory Optimization Software Licensed by Wyeth Pharmaceuticals
11. Talyst Moves Patient Safety and Inventory Control Beyond the Hospital
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2017)... CT (PRWEB) , ... May 29, 2017 , ... ... to announce a new training program for Recovery Coaches who are seeking opportunities ... emergency rooms, court systems, treatment centers, and others. Recovery Coaching and Professionalism© was ...
(Date:5/29/2017)... Pittsburgh, PA (PRWEB) , ... May 29, 2017 , ... ... seemingly simple question: How do doctors determine if someone is cured? The virus has ... the most expensive and time-consuming tests. , Scientists at the University of Pittsburgh’s Graduate ...
(Date:5/28/2017)... ... 2017 , ... Viewers likely know Rob Lowe from such 80s hits as ... his work on NBC’s The West Wing and Parks and Recreation. But recently, Lowe’s ... which puts the spotlight on important modern-day issues that face today’s society. One of ...
(Date:5/27/2017)... ... ... Most us are familiar with the sound of occasional popping joints that ... shows that certain people who experience consistent joint popping, grating and grinding are ... opportunity to treat patients before the problem becomes pronounced, potentially hedging off more severe ...
(Date:5/26/2017)... ... ... Amir Qureshi, MD is the first physician in Arkansas to implant Nuvecta’s Algovita® ... Algovita SCS System has been FDA approved as a treatment option for chronic intractable ... the most powerful SCS system and the only stretchable lead on the market. This ...
Breaking Medicine News(10 mins):
(Date:5/9/2017)... 2017  Oramed Pharmaceuticals Inc. (NASDAQ: ... company focused on the development of oral drug ... Property Office has granted Oramed a patent titled, ... The patent covers Oramed,s invention of an oral ... an incretin hormone that stimulates the secretion of ...
(Date:5/6/2017)... , May 5, 2017  May is Stroke ... one of the most important methods to prevent a ... the Centers for Disease Control and Prevention, undetected and ... 1 Omron, the global leader in personal heart ... the elimination of heart attack and stroke and is ...
(Date:5/4/2017)... SAN DIEGO , May 4, 2017 /PRNewswire/ ... Annual Clinical and Scientific Meeting— OBP Medical , a ... today announced the launch of a new extra-small size ... and ER-SPEC vaginal specula. Already available in ... extra-large sizes makes OBP Medical,s line of single-use lighted ...
Breaking Medicine Technology: